Physical activity decreases cancer burden by alleviating immunosenescence-related inflammation and improving overall immunity https://t.co/3tLuB6ZmOB @OncoAlert
Leucovorin saves lives in cancer care, protects patients on high-dose methotrexate + boosts the impact of fluorouracil. Unproven claims risk shortages, putting cancer patients at risk. Let’s keep treatment decisions rooted in sound science. Full statement: https://t.co/XycOXCkZ6P
Belantamab/bortezomib/dexa (BVd) had a much better PFS than dara/bortezomib/dex (DVd) in a Phase 3 trial.
What are we to make of this result?
Lets analyze this in detail!
An educational thread on appraisal, and my thoughts on how this may affect my practice/thinking.
#mmsm
It’s been the winter/summer of bispecifics….in the past 10 months, we have had 6 approvals! 😨😱 #oncopharm
1) teclistamab
2) mosunetuzumab
3) epcoritamab
4) glofitamab
5) talquetamab
6) elranatamab
Great for patients… now to figure out the how/what/where/when/WHO!!!
🚨🚨Headline results of SWOG S1826 showing that Nivolumab-AVD has better PFS than brentuximab vedotin-AVD in the upfront treatment of Hodgkin lymphoma, with less toxicity, a 🧵👇🏻
#ASCO23#lymsm
Epcoritamab FDA approved for R/R DLBCL!
Take a listen to our recent @WolverHeme podcast with @VictoriaNachar@LymphClinician and @ajperissinotti “Tinder for T cells” discussing the bispecific antibodies in DLBCL! https://t.co/6W8yLGGGyI
Pola+R-CHP approved for upfront DLBCL. However, no improvement in OS or QOL compared to standard R-CHOP. We’re talking about a 6.5% absolute difference in 2-year PFS here with a major increase in cost. This is a marginal gain, not a game changer 🤷🏻♂️ #lymsm https://t.co/1vDKr99UUR
So, sadly many of my #myeloma patients will not be able to afford basic needs in order to pay $1000 a month copays for oral cancer medications. Or they will go without life-extending treatment :-( The situation is dire!
Of all the interventions we do in myeloma clinic, the one I hate most is doublet maintenance for high-risk. Weak evidence base, huge time-toxicity and opportunity cost, and I doubt we truly are changing the natural history of true high-risk disease.
#mmsm
The first randomized trial of CAR-T in multiple myeloma.
https://t.co/7HSW4ihEZP
Ide-cel versus a choice of five regimens for relapsed multiple myeloma!
Lots to learn and process from this trial- so let us get started with this deep-dive 🧵
#mmsm
Happy to be proven wrong with high quality data.
1) KRd no better than VRd for ND high risk
2) Isatuximab no better than daratumumab for gain1q
3) Selinexor no better than anything else for del17p
Please don’t let marketing/uncontrolled studies/subgroups convince you!
#mmsm